↓ Skip to main content

Drug-induced lupus with leukocytoclastic vasculitis: a rare expression associated with adalimumab

Overview of attention for article published in Anais Brasileiros de Dermatologia, June 2015
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
18 Dimensions

Readers on

mendeley
30 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Drug-induced lupus with leukocytoclastic vasculitis: a rare expression associated with adalimumab
Published in
Anais Brasileiros de Dermatologia, June 2015
DOI 10.1590/abd1806-4841.20153834
Pubmed ID
Authors

Carolina Forte Amarante, Livia Mendes Sabia Acedo, Fátima Maria de Oliveira Rabay, Benedito do Espírito Santo Campos, Márcia Lanzoni de Alvarenga Lira, Samuel Henrique Mandelbaum

Abstract

TNF alpha antagonist-induced lupus-like syndrome is a rare condition which predominantly affects women (4:1). The average age of onset is 46-51 years. It occurs after exposure to TNF alpha antagonist and disappears after discontinuation of such agents. The pathogenic mechanism for development of the TNF alpha antagonist-induced lupus-like syndrome is not fully defined. It is believed that the medication induces apoptosis, leading to an accumulation of nucleosomal antigens of apoptotic cells. This would cause autoantibodies to be produced by susceptible individuals. The most common cutaneous manifestations include maculopapular exanthem, malar rash, alopecia, photosensitivity and, more rarely, vasculitis. Extracutaneous manifestations include: fever, weight loss, arthritis or arthralgia, myositis and hematological abnormalities. Antinuclear antibody may be positive in 80% of cases and anti-histone antibody is considered a disease marker for TNF alpha antagonist-induced lupus-like syndrome. Treatment corresponds to drug discontinuation. We report a rare case of sub-acute cutaneous lupus erythematosus with leukocytoclastic vasculitis induced by adalimumab in a 42-year-old patient.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 30 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 3%
Unknown 29 97%

Demographic breakdown

Readers by professional status Count As %
Student > Postgraduate 5 17%
Student > Ph. D. Student 5 17%
Student > Master 4 13%
Student > Doctoral Student 1 3%
Unspecified 1 3%
Other 3 10%
Unknown 11 37%
Readers by discipline Count As %
Medicine and Dentistry 7 23%
Psychology 2 7%
Nursing and Health Professions 1 3%
Unspecified 1 3%
Pharmacology, Toxicology and Pharmaceutical Science 1 3%
Other 1 3%
Unknown 17 57%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 August 2015.
All research outputs
#23,319,379
of 25,986,827 outputs
Outputs from Anais Brasileiros de Dermatologia
#6
of 6 outputs
Outputs of similar age
#241,691
of 282,785 outputs
Outputs of similar age from Anais Brasileiros de Dermatologia
#16
of 17 outputs
Altmetric has tracked 25,986,827 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 6 research outputs from this source. They receive a mean Attention Score of 1.5. This one scored the same or higher as 0 of them.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 282,785 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.